Frequently asked questions about medical abortion

Contraception

Volumn 74, Issue 1, 2006, Pages 3-10

  von Hertzen, Helena ^a   Baird, David ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Medical abortion; Medical abortion regimens; Post abortion care; Pre abortion care

Indexed keywords

ABORTIVE AGENT; CONTRACEPTIVE AGENT; GEMEPROST; MEDROXYPROGESTERONE; MIFEPRISTONE; MISOPROSTOL; PROSTAGLANDIN;

ABORTION; AMENORRHEA; ANTIBIOTIC THERAPY; BIRTH DEFECT; BLEEDING; CLINICAL PRACTICE; CONSENSUS; COUNSELING; ECTOPIC PREGNANCY; FAMILY PLANNING; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; HEALTH CARE PERSONNEL; HUMAN; INFECTION; ITALY; MEDICAL LITERATURE; MEDICAL RESEARCH; MENSTRUAL CYCLE; OVULATION; PAIN; PELVIC INFLAMMATORY DISEASE; PREGNANCY TERMINATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIRENOMELIA;

ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; CONSENSUS DEVELOPMENT CONFERENCES; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; CONTRACEPTION; COUNSELING; FEMALE; GESTATIONAL AGE; HEALTH PERSONNEL; HUMANS; ITALY; MIFEPRISTONE; PREGNANCY; PROSTAGLANDINS; UTERINE HEMORRHAGE;

EID: 33745053904     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.03.029     Document Type: Review

References (45)

1. Slade P., Heke S., Fletcher J., et al. A comparison of medical and surgical termination of pregnancy: choice, emotional impact and satisfaction with care. Br J Obstet Gynaecol 105 (1998) 1288-1295
2. Henshaw R.C., Naji S.A., Russell I.T., et al. Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. Br Med J 307 (1993) 714-717
3. Honkanen H., and von Hertzen H. Users' perspectives on medical abortion in Finland. Contraception 65 (2002) 419-423
4. Honkanen H., Piaggio G., von Hertzen H., et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion: II. Side effects and women's perceptions. Br J Obstet Gynaecol 111 (2004) 1-11
5. National evidence-based clinical guideline: the care of women requesting induced abortion. Updated guidelines (2004), Royal College of Obstetricians and Gynaecologists, London
6. Smith S.K., and Baird D.T. The use of 16-16 dimethyl trans delta 2 PGE1 methyl ester (ONO 802) vaginal suppositories for the termination of early pregnancy. A comparative study. Br J Obstet Gynaecol 87 (1980) 712-717
7. Chan Y.F., Ho P.C., and Ma H.K. Blood loss in termination of early pregnancy by vacuum aspiration and by combination of mifepristone and gemeprost. Contraception 47 (1993) 85-95
8. Hill N.C., Selinger M., Ferguson J., et al. The placental transfer of mifepristone during the second trimester and its influence upon maternal and fetal steroid concentrations. Br J Obstet Gynaecol 97 (1990) 406-411
9. Vogel D., Burkhardt T., Rentsch K., et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol 191 (2004) 2168-2173
10. Xu J., Chen H., Ma T., et al. Termination of early pregnancy in the scarred uterus with mifepristone and misoprostol. Int J Gynecol Obstet 72 (2001) 245-251
11. Stevenson M.M., and Radcliffe K.W. Preventing pelvic infection after abortion. Int J STD AIDS 6 (1995) 305-312
12. Penney G.C. Preventing infective sequelae of abortion. Hum Reprod 12 Suppl 11 (1997) 107-112
13. Blackwell A.L., Thomas P.D., Wareham K., et al. Health gains from screening for infection of the lower genital tract in women attending for termination of pregnancy. Lancet 342 (1993) 206-210
14. Fiala C., Fux M., and Gemzell-Danielsson K. Rh-prophylaxis in early abortion. Acta Obstet Gynecol Scand 82 (2003) 892-903
15. Jabara S., and Barnhart K.T. Is Rh immune globulin needed in early first-trimester abortion? A review. Am J Obstet Gynecol 188 (2003) 623-627
16. Thong K.J., Norman J.E., and Baird D.T. Changes in the concentration of alpha-fetoprotein and placental hormones following two methods of medical abortion in early pregnancy. Br J Obstet Gynaecol 100 (1993) 1111-1114
17. Edwards J., and Carson S.A. New technologies permit safe abortion at less than 6 weeks' gestation and provide timely detection of ectopic gestation. Am J Obstet Gynecol 176 (1997) 1101-1106
18. Fiala C., Safar P., Bygdeman M., et al. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol 109 (2003) 190-195
19. World Health Organization Task Force on Post-Ovulatory Methods for Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. Br Med J 307 (1993) 532-537
20. World Health Organization Task Force on Post-Ovulatory Methods for Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomized trial. Br J Obstet Gynaecol 107 (2000) 524-530
21. World Health Organization Task Force on Post-Ovulatory Methods for Fertility Regulation. Medical abortion at 57 to 63 days gestation with a lower dose of mifepristone and gemeprost. A randomized controlled trial. Acta Obstet Gynecol Scand 80 (2001) 447-451
22. McKinley C., Thong K.J., and Baird D.T. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod 8 (1993) 1502-1505
23. Safe abortion: technical and policy guidance for health systems (2003), World Health Organization, Geneva
24. Ashok P.W., Templeton A., Wagaarachchi P.T., et al. Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases. Br J Obstet Gynaecol 109 (2002) 1281-1289
25. von Hertzen H., Honkanen H., Piaggio G., et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion: I. Efficacy. Br J Obstet Gynaecol 110 (2003) 808-818
26. El-Refaey H., Rajasekar D., Abdalla M., et al. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 332 (1995) 983-987
27. Schaff E.A., Fielding S.L., and Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception 66 (2002) 247-250
28. Tang O.S., Schweer H., Seyberth H.W., et al. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 17 (2002) 332-336
29. Swahn M.L., and Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynaecol 95 (1988) 126-134
30. Schaff E.A., Fielding S.L., Westhoff C., et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA 284 (2000) 1948-1953
31. Schaff E.A., Fielding S.L., and Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception 64 (2001) 81-85
32. Creinin M.D., Fox M.L., Teal S., et al. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol 103 (2004) 851-859
33. Westhoff C., Dasmahapatra R., Winikoff B., et al. Predictors of analgesia use during supervised medical abortion. Contraception 61 (2000) 225-229
34. Westhoff C., Dasmahapatra R., and Schaff E. Analgesia during at-home use of misoprostol as part of a medical abortion regimen. Contraception 62 (2000) 311-314
35. Acharya G., Haugen M., Brathen A., et al. Role of routine ultrasonography in monitoring the outcome of medical abortion in a clinical setting. Acta Obstet Gynecol Scand 83 (2004) 390-394
36. Cowett A.A., Cohen L.S., Lichtenberg E.S., et al. Ultrasound evaluation of the endometrium after medical termination of pregnancy. Obstet Gynecol 103 (2004) 871-875
37. Shannon C., Brothers L.P., Philip N.M., et al. Infection after medical abortion: a review of the literature. Contraception 70 (2004) 183-190
38. US Food and Drug Administration. FDA public health advisory; sepsis and medical abortion. Available at. www.fda.gov/cder/drug/advisory/mifeprex.htm accessed on February 20, 2006
39. Exelgyn, Periodic safety update no. 16, May 31, 2005.
40. Sitruk-Ware R., and Spitz I.M. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception 68 (2003) 409-420
41. Kotsonis F.N., Dodd D.C., Regnier B., et al. Preclinical toxicology profile of misoprostol. Dig Dis Sci 30 Suppl 11 (1985) 142S-146S
42. Jost A. New data on the hormonal requirements of the pregnant rabbit: partial pregnancies and fetal abnormalities after treatment with a hormonal antagonist at subabortifacient doses. C R Acad Sci 303 (1986) 281-284
43. Lähteenmäki P., Ylöstalo P., Sipinen S., et al. Return of ovulation after abortion and after discontinuation of oral contraceptives. Fertil Steril 34 (1980) 246-249
44. Martin C.W., Brown A.H., and Baird D.T. A pilot study of the effect of methotrexate or combined oral contraceptive on bleeding patterns after induction of abortion with mifepristone and a prostaglandin pessary. Contraception 58 (1998) 99-103
45. Tang O.S., Xu J., Cheng L., et al. The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol: a randomized placebo controlled trial. Hum Reprod 17 (2002) 99-102